ArticleJournal of clinical medicine2023
Switching to Dupilumab from Other Biologics without a Treatment Interval in Patients with Severe Asthma: A Multi-Center Retrospective Study.
Article in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Patterns and Clinical Efficacy of Biologics Switching in Patients With Severe Asthma: A Systematic Review and Meta-Analysis.Allergy · 2026Pooled it
- Treatment of Severe Uncontrolled Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP) with Mepolizumab or Dupilumab: A Preliminary Single-Center Study for Evaluation of Safety and Efficacy.Journal of personalized medicine · 2026Article
- Choosing and switching biologics for patients with severe asthma: Real-world data from the German Asthma Net (GAN).Allergologie select · 2026Article
- Biomarker-Associated Remission After Switching to Dupilumab in Severe Asthma Following Failure of Prior Biologics.Biomedicines · 2025Article
- Persistent Eosinophilic Inflammation Is Not a Feature of Type 2 CRS Patients Failing Anti-IL-5R Therapy and Requiring Class Switching to Anti-IL-4/13.International forum of allergy & rhinology · 2025Article
- Switching biologics in chronic rhinosinusitis with nasal polyps: A multicenter Canadian experience.International forum of allergy & rhinology · 2025Article
- Evaluating Safety and Effectiveness of Switching Biologics in Managing Severe Asthma Patients.Journal of asthma and allergy · 2025Article
- Article
- Monoclonal Antibody Switching in Biologic Treatment of Chronic Rhinosinusitis with Nasal Polyps.Journal of clinical medicine · 2024Article
- Advancing Care in Severe Asthma: The Art of Switching Biologics.Advances in respiratory medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDupilumab is a fully humanized monoclonal antibody that blocks interleukin-4 and interleukin-13 signals. Several large clinical trials have demonstrated the efficacy of dupilumab in patients with severe asthma. However, few studies have examined a switch to dupilumab from other biologics.
methodsThis retrospective, multi-center observational study was conducted by the Okayama Respiratory Disease Study Group. Consecutive patients with severe asthma who were switched to dupilumab from other biologics without a treatment interval between May 2019 and September 2021 were enrolled. Patients with a treatment interval of more than twice the standard dosing interval for the previous biologic prior to dupilumab administration were excluded.
resultsThe median patient age of the 27 patients enrolled in this study was 57 years (IQR, 45-68 years). Eosinophilic chronic rhinosinusitis (ECRS)/chronic rhinosinusitis with nasal polyp (CRSwNP) was confirmed in 23 patients. Previous biologics consisted of omalizumab (n = 3), mepolizumab (n = 3), and benralizumab (n = 21). Dupilumab significantly improved FEV
conclusionsDupilumab was highly effective for the treatment of severe asthma and ECRS/CRSwNP, even in patients switched from other biologics without a treatment interval.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.